Tumor Burden Analysis
Tumor Burden Analysis - Related Videos
03:46
Malassezia-Induced Skin Inflammation and Fungal Burden Analysis in a Murine Model
0 Views •
2025
This video demonstrates Malassezia-induced skin infection in mice. Malassezia oil suspension is applied over the wounded ear, triggering inflammation and swelling of the ear tissue. Later, the ears are dissected, homogenized, and spread on an agar plate for growth. The number of colonies indicates the fungal burden resulting from skin inflammation.
02:03
Assessing Bacterial Burden in the Mouse Spleen for Infection Studies
0 Views •
2026
Source: Madenspacher, J. H. and Fessler, M. B. A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice. J. Vis. Exp. (2016)This video demonstrates the process of quantifying bacterial load in the spleen of an infected mouse to assess the severity of infection. The homogenized spleen is serially diluted and plated to determine total bacterial burden. The resulting data provide insights into host-pathogen interactions within...
04:29
Monitoring Neutrophil Recruitment Dynamics and Bacterial Burden at the Infection Site in a Murine Model
0 Views •
2025
This video demonstrates in vivo imaging to study the neutrophil recruitment dynamics at an infection site in an immunocompromised, transgenic mouse with GFP-expressing neutrophils. It involves injecting luminescent bacteria to cause an infection. This leads to neutrophil recruitment to the infection site, whose tracking is done by imaging.
03:23
Measurement of the In Vivo Burden of Bacteria Expressing Luciferase in an Insect Larva
0 Views •
2025
This video showcases the in vivo bacterial burden measurement using Bacillus Calmette-Guérin, BCG, lux-infected insect larvae. The process involves larval homogenization, treatment with a luciferase substrate, and bioluminescence measurement to determine relative light units that correlate with bacterial burden.
07:12
Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
0 Views •
Cited by 29 •
2016
Bioluminescence imaging is a well-known tool for localizing tumors and metastases, but quantification of these images often requires complex calculations and particular instruments. We describe the easy-to-use luminoscore method, based on precise acquisition conditions, requiring no calculations, and enabling tumor burden and treatment response to be monitored in mouse models.
FAQs
The direction and magnitude of change provide a framework for interpreting treatment effects. A decreasing burden can support regression, an increasing burden can indicate progression, and little change may represent stability. Repeated assessments are therefore more informative than a single measurement when clinicians monitor disease during therapy and consider whether the current treatment remains appropriate.
Each source describes a different aspect of malignant disease. Computed tomography and magnetic resonance imaging support estimates of tumor size or volume, whereas pathology can assess malignant cells and biomarkers provide additional measurable information. Combining these sources can give a broader view of disease extent than relying on one measurement alone.
Standardized burden measurements make assessments more consistent across time and among patients or studies. This consistency helps distinguish meaningful changes from differences caused by measurement practices. In clinical research, standardized approaches strengthen trial endpoints, making it easier to assess and compare the effects of novel anticancer therapies.
Beyond describing disease extent, the measurements can support prognosis and treatment decisions. Clinicians can place current findings in the context of earlier assessments to evaluate whether disease is regressing, progressing, or remaining stable. This longitudinal perspective connects quantitative observations with decisions about ongoing cancer management.
A general workflow begins with a quantitative assessment using medical imaging, commonly computed tomography or magnetic resonance imaging, to estimate tumor size or volume. Pathology and biomarker measurements may then provide complementary information. Repeating these assessments over time allows the results to be compared and interpreted in relation to therapy.
It is particularly valuable when a study must measure whether an anticancer therapy changes disease over time. Quantitative burden assessments can serve as clinical trial endpoints, while repeated measurements help characterize treatment response. Their standardized use also supports evaluation of novel therapies by providing a consistent basis for comparing outcomes.